| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC | 50% | 0% | $175,394,186 | +$8,832,244 | 5,189,177 | +5.3% | Ligand Pharmaceuticals Incorporated | 06 Nov 2025 |
| 3i, LP | 9.9% | 303,138 | 3i, LP | 01 Jul 2025 | ||||
| Murchinson Ltd. | 9.1% | $9,464,000 | 280,000 | Murchinson Ltd. | 30 Sep 2025 | |||
| Friedberg Ezra M | 8.3% | 250,121 | Ezra Friedberg | 01 Jul 2025 | ||||
| Ikarian Capital, LLC | 6.1% | $6,300,590 | 186,408 | Ikarian Capital, LLC | 30 Sep 2025 |
As of 30 Sep 2025, 14 institutional investors reported holding 462,762 shares of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS). This represents 15% of the company’s total 3,076,923 outstanding shares.
The largest institutional shareholders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) together control 15% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Murchinson Ltd. | 9.1% | 280,000 | 1.5% | $7,840,000 | |
| VANGUARD GROUP INC | 2.2% | 66,836 | 0% | $1,871,408 | |
| Ikarian Capital, LLC | 2% | 62,451 | 0.4% | $1,748,628 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.69% | 21,245 | 0.02% | $594,860 | |
| DIADEMA PARTNERS LP | 0.34% | 10,498 | 0.2% | $293,944 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.34% | 10,330 | 0% | $289,240 | |
| Knott David M Jr | 0.2% | 6,112 | 0.07% | $171,136 | |
| Persistent Asset Partners Ltd | 0.08% | 2,403 | 0.05% | $67,284 | |
| Steward Partners Investment Advisory, LLC | 0.06% | 1,910 | 0% | $53,480 | |
| Tower Research Capital LLC (TRC) | 0.03% | 827 | 0% | $23,156 | |
| UBS Group AG | 0% | 137 | 0% | $3,836 | |
| BANK OF AMERICA CORP /DE/ | 0% | 11 | 0% | $308 | |
| CITIGROUP INC | 0% | 1 | 0% | $28 | |
| JPMORGAN CHASE & CO | 0% | 1 | 0% | $28 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 462,762 | $12,957,336 | +$12,957,336 | $28.00 | 14 |